Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 8 (August)

1. Involvement of neutral endopeptidase in neoplastic progression.
   Biochim Biophys Acta, 1751(1): 52-9. [Abstract] [Full-text]
2. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.
   Cancer Sci, 96(7): 425-33. [Abstract] [Full-text]
3. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.
   Mol Carcinog, 44(1): 1-10. [Abstract] [Full-text]
4. Highly specific expression of luciferase gene in lungs of naïve nude mice directed by prostate-specific antigen promoter.
   Biochem Biophys Res Commun, 334(4): 1287-91. [Abstract] [Full-text]
5. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
   Cancer Res, 65(15): 6967-75. [Abstract] [Full-text]
6. Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis.
   Cancer Res, 65(15): 6773-9. [Abstract] [Full-text]
7. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells.
   Cancer Res, 65(15): 6719-25. [Abstract] [Full-text]
8. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
   Cancer Res, 65(15): 6692-700. [Abstract] [Full-text]
9. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
   Cancer Res, 65(15): 6640-50. [Abstract] [Full-text]
10. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    J Natl Cancer Inst, 97(15): 1132-7. [Abstract] [Full-text]
11. Alteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines.
    Acta Oncol, 44(3): 299-303. [Abstract] [Full-text]
12. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model.
    Acta Oncol, 44(3): 293-8. [Abstract] [Full-text]
13. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Acta Oncol, 44(3): 282-92. [Abstract] [Full-text]
14. Diet, lifestyle and risk of prostate cancer.
    Acta Oncol, 44(3): 277-81. [Abstract] [Full-text]
15. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy.
    Acta Oncol, 44(3): 265-76. [Abstract] [Full-text]
16. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?
    Acta Oncol, 44(3): 255-64. [Abstract] [Full-text]
17. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression.
    Genes Dev, 19(15): 1779-86. [Abstract] [Full-text]
18. Statins and prostate cancer risk: a case-control study.
    Am J Epidemiol, 162(4): 318-25. [Abstract] [Full-text]
19. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region.
    Hum Genet, 117(4): 307-16. [Abstract] [Full-text]
20. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
    Nature, 436(7051): 725-30. [Abstract] [Full-text]
21. MR-guided interventions for prostate cancer.
    Magn Reson Imaging Clin N Am, 13(3): 491-504. [Abstract] [Full-text]
22. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
    Am J Med, 118(8): 850-7. [Abstract] [Full-text]
23. Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway.
    Cancer, 104(4): 747-51. [Abstract] [Full-text]
24. Improving the quality of life of patients with prostate carcinoma: a randomized trial testing the efficacy of a nurse-driven intervention.
    Cancer, 104(4): 752-62. [Abstract] [Full-text]
25. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.
    J Steroid Biochem Mol Biol, 96(3): 251-8. [Abstract] [Full-text]
26. High prostate cancer mortality in Norway: influence of Cancer Registry information?
    APMIS, 113(7): 542-9. [Abstract] [Full-text]
27. Evaluation of the Sinmed Mastercouch as replacement for a standard couch.
    Radiother Oncol, 75(2): 227-36. [Abstract] [Full-text]
28. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Wien Klin Wochenschr, 117(13): 457-61. [Abstract] [Full-text]
29. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis.
    Oncogene, 24(34): 5375-83. [Abstract] [Full-text]
30. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis.
    Oncogene, 24(34): 5389-95. [Abstract] [Full-text]
31. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
    Lancet, 366(9485): 572-8. [Abstract] [Full-text]
32. Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis.
    Cancer Genet Cytogenet, 161(2): 97-103. [Abstract] [Full-text]
33. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk.
    Br J Cancer, 93(4): 493-7. [Abstract] [Full-text]
34. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    BJU Int, 96(4): 640-6. [Abstract] [Full-text]
35. Local steroid application during nerve-sparing radical retropubic prostatectomy.
    BJU Int, 96(4): 533-5. [Abstract] [Full-text]
36. A comparison of the biological features between prostate cancers arising in the transition and peripheral zones.
    BJU Int, 96(4): 528-32. [Abstract] [Full-text]
37. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    BJU Int, 96(4): 521-7. [Abstract] [Full-text]
38. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study.
    BJU Int, 96(4): 514-20. [Abstract] [Full-text]
39. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
    BJU Int, 96(4): 508-13. [Abstract] [Full-text]
40. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    BJU Int, 96(4): 503-7. [Abstract] [Full-text]
41. Construction of tissue microarrays from prostate needle biopsy specimens.
    Br J Cancer, 93(4): 478-82. [Abstract] [Full-text]
42. Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway.
    Oncogene, 24(35): 5510-20. [Abstract] [Full-text]
43. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.
    Cancer Lett, 227(2): 213-22. [Abstract] [Full-text]
44. Protective effects of black tea extract on testosterone induced oxidative damage in prostate.
    Cancer Lett, 227(2): 125-32. [Abstract] [Full-text]
45. Intraoperative fluoroscopic dose assessment in prostate brachytherapy patients.
    Int J Radiat Oncol Biol Phys, 63(1): 301-7. [Abstract] [Full-text]
46. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important?
    Int J Radiat Oncol Biol Phys, 63(1): 155-63. [Abstract] [Full-text]
47. Rectal fistulas after prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 63(1): 150-4. [Abstract] [Full-text]
48. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Int J Radiat Oncol Biol Phys, 63(1): 141-9. [Abstract] [Full-text]
49. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
    Int J Radiat Oncol Biol Phys, 63(1): 134-40. [Abstract] [Full-text]
50. Retrospective analysis of prostate cancer patients with implanted gold markers using off-line and adaptive therapy protocols.
    Int J Radiat Oncol Biol Phys, 63(1): 123-33. [Abstract] [Full-text]
51. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
    Int J Radiat Oncol Biol Phys, 63(1): 238-46. [Abstract] [Full-text]
52. INSPstI polymorphism and prostate cancer in African-American men.
    Prostate, 65(1): 83-7. [Abstract] [Full-text]
53. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk.
    Prostate, 65(1): 58-65. [Abstract] [Full-text]
54. BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis.
    Prostate, 65(1): 35-43. [Abstract] [Full-text]
55. Role of endothelin axis in progression to aggressive phenotype of prostate adenocarcinoma.
    Prostate, 65(1): 27-34. [Abstract] [Full-text]
56. IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer.
    Prostate, 65(1): 44-51. [Abstract] [Full-text]
57. Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.
    Prostate, 65(1): 20-6. [Abstract] [Full-text]
58. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo.
    Prostate, 65(1): 10-9. [Abstract] [Full-text]
59. Gene expression profiling in single cells within tissue.
    Nat Methods, 2(9): 663-5. [Abstract] [Full-text]
60. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience.
    Radiology, 236(3): 903-10. [Abstract] [Full-text]
61. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids.
    FEBS Lett, 579(20): 4541-4549. [Abstract] [Full-text]
62. CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus.
    Oncogene, 24(36): 5543-51. [Abstract] [Full-text]
63. Pim family kinases enhance tumor growth of prostate cancer cells.
    Mol Cancer Res, 3(8): 443-51. [Abstract] [Full-text]
64. Quality of prostate carcinoma care in a statewide public assistance program.
    Cancer, 104(5): 985-92. [Abstract] [Full-text]
65. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.
    Cancer, 104(5): 962-7. [Abstract] [Full-text]
66. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues.
    Cancer, 104(5): 891-905. [Abstract] [Full-text]
67. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Cancer, 104(5): 993-1003. [Abstract] [Full-text]
68. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases.
    Prostate, 65(2): 178-87. [Abstract] [Full-text]
69. Familial association of prostate cancer with other cancers in the Swedish Family-Cancer Database.
    Prostate, 65(2): 188-94. [Abstract] [Full-text]
70. Association of a CAV-1 haplotype to familial aggressive prostate cancer.
    Prostate, 65(2): 171-7. [Abstract] [Full-text]
71. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells.
    Prostate, 65(2): 141-50. [Abstract] [Full-text]
72. Heparin affin regulatory peptide is a key player in prostate cancer cell growth and angiogenicity.
    Prostate, 65(2): 151-8. [Abstract] [Full-text]
73. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells.
    Prostate, 65(2): 130-40. [Abstract] [Full-text]
74. Ethnic and racial differences in prostate stromal estrogen receptor alpha.
    Prostate, 65(2): 101-9. [Abstract] [Full-text]
75. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
    Prostate, 65(2): 124-9. [Abstract] [Full-text]
76. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis.
    Prostate, 65(2): 110-6. [Abstract] [Full-text]
77. A variant of the alpha-methyl-acyl-CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer.
    Prostate, 65(2): 117-23. [Abstract] [Full-text]
78. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
    Int J Cancer, 117(2): 221-9. [Abstract] [Full-text]
79. Androgens induce CD-9 in human prostate tissue.
    Int J Androl, 28(5): 291-6. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.